Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206 · see citing works

Plat-E: an efficient and stable system for transient packaging of retroviruses

MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works

Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 716 · see citing works

B cells acquire antigen from target cells after synapse formation

Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629 · see citing works

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 518 · see citing works

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · see citing works

The Cytokine RANKL Produced by Positively Selected Thymocytes Fosters Medullary Thymic Epithelial Cells that Express Autoimmune Regulator

Hikosaka, Y., Nitta, T., Ohigashi, I., Yano, K., Ishimaru, N., Hayashi, Y., Matsumoto, M., Matsuo, K., Penninger, J. M., Takayanagi, H., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.018 · Cited by 433 · see citing works

Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells

Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 411 · see citing works

Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4 + CD25 + regulatory T‐cell‐mediated suppression

Oderup, C., Cederbom, L., Makowska, A. M., Cilio, C., & Ivars, F. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02362.x · Cited by 338 · see citing works

Rac-dependent trans-endocytosis of ephrinBs regulates Eph–ephrin contact repulsion

Marston, D. J., Dickinson, S., & Nobes, C. D. (2003) · Nature Cell Biology · doi:10.1038/ncb1044 · Cited by 301 · see citing works

CD40 Ligation Releases Immature Dendritic Cells from the Control of Regulatory CD4+CD25+ T Cells

Serra, P., Amrani, A., Yamanouchi, J., Han, B., Thiessen, S., Utsugi, T., Verdaguer, J., & Santamaría, P. (2003) · Immunity · doi:10.1016/s1074-7613(03)00327-3 · Cited by 291 · see citing works

Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response

Davis, D. M. (2007) · Nature reviews. Immunology · doi:10.1038/nri2020 · Cited by 288 · see citing works

CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M. W., Der, S. D., Kang, J., & Chambers, C. A. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266 · see citing works

Cutting Edge: Lymphoproliferative Disease in the Absence of CTLA-4 Is Not T Cell Autonomous

Bachmann, M. F., Köhler, G., Ecabert, B., Mak, T. W., & Köpf, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1128 · Cited by 235 · see citing works

Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression

Chuang, E., Alegre, M., Duckett, C. S., Noel, P. J., Heiden, M. G. V., & Thompson, C. B. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.144 · Cited by 225 · see citing works

Regulation of Cell Surface Expression of CTLA-4 by Secretion of CTLA-4-Containing Lysosomes Upon Activation of CD4+ T Cells

Iida, T., Ohno, H., Nakaseko, C., Sakuma, M., Takeda‐Ezaki, M., Arase, H., Kominami, E., Fujisawa, T., & Saito, T. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5062 · Cited by 173 · see citing works

The bride of sevenless and sevenless interaction: Internalization of a transmembrane ligand

Cagan, R. L., Krämer, H., Hart, A. C., & Zipursky, S. L. (1992) · Cell · doi:10.1016/0092-8674(92)90442-f · Cited by 171 · see citing works

CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity

Schmidt, E. M., Wang, C. J., Ryan, G. A., Clough, L. E., Qureshi, O., Goodall, M. D., Abbas, A. K., Sharpe, A. H., Sansom, D. M., & Walker, L. S. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.274 · Cited by 155 · see citing works

Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation

Choi, J.-M., Ahn, M.-H., Chae, W.-J., Jung, Y.-G., Park, J.-C., Song, H.-M., Kim, Y.-E., Shin, J.-A., Park, C.-S., Park, J.-W., et al. (2006) · Nature Medicine · doi:10.1038/nm1385 · Cited by 138 · see citing works

Capture of Target Cell Membrane Components via Trogocytosis Is Triggered by a Selected Set of Surface Molecules on T or B Cells

Hudrisier, D., Aucher, A., Puaux, A., Bordier, C., & Joly, E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3637 · Cited by 100 · see citing works

Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells

Aucher, A., Magdeleine, E., Joly, E., & Hudrisier, D. (2008) · Blood · doi:10.1182/blood-2008-01-134155 · Cited by 98 · see citing works

Acquisition of Suppressive Function by Activated Human CD4+CD25− T Cells Is Associated with the Expression of CTLA-4 Not FoxP3

Zheng, Y., Manzotti, C. N., Burke, F., Dussably, L., Qureshi, O., Walker, L. S. K., & Sansom, D. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1683 · Cited by 86 · see citing works

Exocytosis of CTLA-4 Is Dependent on Phospholipase D and ADP Ribosylation Factor-1 and Stimulated during Activation of Regulatory T Cells

Mead, K. I., Zheng, Y., Manzotti, C. N., Perry, L., Liu, M. K. P., Burke, F., Powner, D., Wakelam, M. J. O., & Sansom, D. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4803 · Cited by 86 · see citing works

Lack of Intrinsic CTLA-4 Expression Has Minimal Effect on Regulation of Antiviral T-Cell Immunity

Homann, D., Dummer, W., Wolfe, T., Rodrigo, E., Theofilopoulos, A. N., Oldstone, M. B. A., & von Herrath, M. G. (2005) · Journal of Virology · doi:10.1128/jvi.80.1.270-280.2006 · Cited by 56 · see citing works

Membranous Structures Transfer Cell Surface Proteins Across NK Cell Immune Synapses

Williams, G. S., Collinson, L., Brzostek, J., Eissmann, P., Almeida, C. R., McCann, F. E., Burshtyn, D. N., & Davis, D. M. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00603.x · Cited by 51 · see citing works

Preferential Transfer of Certain Plasma Membrane Proteins onto T and B Cells by Trogocytosis

Daubeuf, S., Aucher, A., Bordier, C., Salles, A., Serre, L., Gaibelet, G., Faye, J., Favre, G., Joly, E., & Hudrisier, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008716 · Cited by 45 · see citing works

Trans-endocytosis of CD47 and SHPS-1 and its role in regulation of the CD47–SHPS-1 system

Kusakari, S., Ohnishi, H., Jin, F.-J., Kaneko, Y., Murata, T., Murata, Y., Okazawa, H., & Matozaki, T. (2008) · Journal of Cell Science · doi:10.1242/jcs.025015 · Cited by 33 · see citing works

TcR‐induced regulated secretion leads to surface expression of CTLA‐4 in CD4+CD25+ T cells

Catálfamo, M., Tai, X., Karpova, T., McNally, J. G., & Henkart, P. A. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02822.x · Cited by 21 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

Regulatory T cells: mechanisms of differentiation and function

Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · see citing works

Immune Checkpoint Blockade in Cancer Therapy

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · see citing works

The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · see citing works

Regulatory T cells in cancer immunotherapy

Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860 · see citing works

The role of interleukin-2 during homeostasis and activation of the immune system

Boyman, O., & Sprent, J. (2012) · Nature reviews. Immunology · doi:10.1038/nri3156 · Cited by 1,656 · see citing works

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,384 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211 · see citing works

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Vaddepally, R. K., Kharel, P., Pandey, R. K., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,189 · see citing works

Regulatory T Cells and Human Disease

Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,133 · see citing works

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,046 · see citing works

T cells in health and disease

Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,060 · see citing works

CD28 Costimulation: From Mechanism to Therapy

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937 · see citing works

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdiş, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 982 · see citing works

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 915 · see citing works

Coinhibitory Pathways in Immunotherapy for Cancer

Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 912 · see citing works

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892 · see citing works

Tumor-infiltrating lymphocytes in the immunotherapy era

Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 887 · see citing works

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

Kuehn, H. S., Ouyang, W., Lo, B., Deenick, E. K., Niemela, J. E., Avery, D. T., Schickel, J., Tran, D. Q., Stoddard, J. L., Zhang, Y., et al. (2014) · Science · doi:10.1126/science.1255904 · Cited by 854 · see citing works

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 836 · see citing works

Monoclonal Antibodies in Cancer Therapy

Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 845 · see citing works

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 786 · see citing works

Molecular Mechanisms of Treg-Mediated T Cell Suppression

Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 760 · see citing works

Intercellular communication: diverse structures for exchange of genetic information

Mittelbrunn, M., & Sánchez‐Madrid, F. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3335 · Cited by 661 · see citing works

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 633 · see citing works

Cancer immunotherapies targeting the PD-1 signaling pathway

Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 641 · see citing works

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J. L., Ruhland, M. K., Kersten, K., Abushawish, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629 · see citing works

tTregs, pTregs, and iTregs: similarities and differences

Shevach, E. M., & Thornton, A. M. (2014) · Immunological Reviews · doi:10.1111/imr.12160 · Cited by 609 · see citing works

Metabolic barriers to cancer immunotherapy

DePeaux, K., & Delgoffe, G. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00541-y · Cited by 614 · see citing works

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 590 · see citing works

Going viral with cancer immunotherapy

Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3770 · Cited by 590 · see citing works

The pharmacology of second-generation chimeric antigen receptors

van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 561 · see citing works

CD4 and CD8 T lymphocyte interplay in controlling tumor growth

Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 550 · see citing works

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 537 · see citing works

The immunological synapse

Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502 · see citing works

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints

Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 546 · see citing works

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531 · see citing works

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

Joshi, N. S., Akama‐Garren, E. H., Lu, Y., Lee, D.-Y., Chang, G. P., Li, A., DuPage, M. J. P., Tammela, T., Kerper, N. R., Farago, A. F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.006 · Cited by 515 · see citing works

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Coutzac, C., Jouniaux, J.-M., Paci, A., Schmidt, J., Mallardo, D., Seck, A., Asvatourian, V., Cassard, L., Saulnier, P., Lacroix, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16079-x · Cited by 513 · see citing works

Cancer immunotherapies: advances and bottlenecks

Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484 · see citing works

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy

Giles, A. J., Hutchinson, M.-K. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0371-5 · Cited by 498 · see citing works

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490 · see citing works

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.055 · Cited by 441 · see citing works

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 437 · see citing works

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Zhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383 · see citing works

Treg and CTLA-4: Two intertwining pathways to immune tolerance

Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411 · see citing works

<scp>NF</scp>‐κB: roles and regulation in different <scp>CD</scp>4⁺ T‐cell subsets

Oh, H., & Ghosh, S. (2013) · Immunological Reviews · doi:10.1111/imr.12033 · Cited by 408 · see citing works

Regulatory T cells in cardiovascular diseases

Meng, X., Yang, J., Dong, M., Zhang, K., Tu, E., Gao, Q., Chen, W., Zhang, C., & Zhang, Y. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.169 · Cited by 406 · see citing works

From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines

Banchereau, J., Pascual, V., & O’Garra, A. (2012) · Nature Immunology · doi:10.1038/ni.2406 · Cited by 401 · see citing works

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

Zappasodi, R., Serganova, I. S., Cohen, I., Maeda, M., Shindo, M., Şenbabaoğlu, Y., Watson, M. J., Leftin, A., Maniyar, R. R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 395 · see citing works

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives

Thomas, R., Al‐Khadairi, G., Roelands, J. P., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 394 · see citing works

Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4

Wing, J. B., Ise, W., Kurosaki, T., & Sakaguchi, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.006 · Cited by 388 · see citing works

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer

Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368 · see citing works

Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts

Torralba, D., Baixauli, F., Villarroya‐Beltri, C., Fernández‐Delgado, I., Latorre, A., Acín‐Pérez, R., Martin-Cofreces, N. B., Jaso-Tamame, A. L., Iborra, S., Jorge, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05077-9 · Cited by 376 · see citing works

Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer

Jang, J., Hajdu, C. H., Liot, C., Miller, G., Dustin, M. L., & Bar‐Sagi, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.062 · Cited by 373 · see citing works

Antigen Presentation by Extracellular Vesicles from Professional Antigen-Presenting Cells

Lindenbergh, M. F. S., & Stoorvogel, W. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055700 · Cited by 376 · see citing works

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 374 · see citing works

Confusing signals: Recent progress in CTLA-4 biology

Walker, L. S. K., & Sansom, D. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.001 · Cited by 362 · see citing works

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Yang, C. Q., Xia, B.-R., Zhang, Z.-C., Zhang, Y., Lou, G., & Jin, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 354 · see citing works

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335 · see citing works

Transfer of extracellular vesicles during immune cell‐cell interactions

Gutiérrez‐Vázquez, C., Villarroya‐Beltri, C., Mittelbrunn, M., & Sánchez‐Madrid, F. (2012) · Immunological Reviews · doi:10.1111/imr.12013 · Cited by 325 · see citing works

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 325 · see citing works

Understanding and treating the inflammatory adverse events of cancer immunotherapy

Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319 · see citing works

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy

Basu, A. B., Ramamoorthi, G., Albert, G. K., Gallen, C., Beyer, A., Snyder, C., Koski, G. K., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 318 · see citing works

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 312 · see citing works

B7 family checkpoint regulators in immune regulation and disease

Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 308 · see citing works

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 307 · see citing works

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Koyama, S., & Nishikawa, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002591 · Cited by 307 · see citing works

Cancer and the Immune System: Basic Concepts and Targets for Intervention

Pardoll, D. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 302 · see citing works

Regulatory T cells in the treatment of disease

Sharabi, A., Tsokos, M., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297 · see citing works

CTLA-4: From mechanism to autoimmune therapy

Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 299 · see citing works

Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions

Grant, C. R., Liberal, R., Mieli‐Vergani, G., Vergani, D., & Longhi, M. S. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.012 · Cited by 292 · see citing works

HLA-G: At the Interface of Maternal–Fetal Tolerance

Ferreira, L. M. R., Meissner, T. B., Tilburgs, T., & Strominger, J. L. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.009 · Cited by 295 · see citing works

Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses

Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 289 · see citing works

Immune mechanisms of toxicity from checkpoint inhibitors

Wang, S. J., Dougan, S. K., & Dougan, M. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.002 · Cited by 292 · see citing works

CD73 expression on extracellular vesicles derived from CD4+CD25+Foxp3+ T cells contributes to their regulatory function

Smyth, L. A., Ratnasothy, K., Tsang, J. Y., Boardman, D. A., Warley, A., Lechler, R. I., & Lombardi, G. (2013) · European Journal of Immunology · doi:10.1002/eji.201242909 · Cited by 275 · see citing works

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions

Zhang, M., Liu, C.-J., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 299 · see citing works

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 266 · see citing works

Regulatory T cells mediate specific suppression by depleting peptide–MHC class II from dendritic cells

Akkaya, B., Oya, Y., Akkaya, M., Souz, J. A. A., Holstein, A. H., Kamenyeva, O., Kabát, J., Matsumura, R., Dorward, D. W., Glass, D. D., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0280-2 · Cited by 266 · see citing works

The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells

Okeke, E. B., & Uzonna, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00680 · Cited by 266 · see citing works

Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases

Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263 · see citing works

Enterocolitis due to immune checkpoint inhibitors: a systematic review

Soularue, É., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D. M., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 263 · see citing works

An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells

Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 256 · see citing works

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

Tai, X., Laethem, F. V., Pobezinsky, L. A., Guinter, T. I., Sharrow, S. O., Adams, A., Granger, L. G., Kruhlak, M. J., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251 · see citing works

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 247 · see citing works

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 246 · see citing works

The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy

Miller, J. F. A. P., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.007 · Cited by 243 · see citing works

CTLA-4-mediated trans-endocytosis in the control of T cell co-stimulation

Ovcinnikovs, V. (2018) · UCL Discovery (University College London)

Investigating transendocytosis mediated by CTLA4

Nguyen, L. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24962

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 50 · see citing works

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 220 · see citing works

Molecular and Cellular Functions of CTLA-4

Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 248 · see citing works